Long COVID / Post-Acute COVID Sequelae (PACVS) — RepurpOS

Disease overview

Alterations

104

Molecular (A)

100

Clinical (B–E)

Direct drugs

546

Via biomarker

125

Natural agents

Natural products

Merged ranked

675

With trial/literature evidence

Sources: Seeds, Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, OSMF Chronic Disease Review, PubMed MeSH · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Spontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely debilitating long COVID in 10-15% at 1 year without intervention

Best-intervention remission

No approved pharmacotherapy; Paxlovid (nirmatrelvir/ritonavir) — PANORAMIC trial showed no reduction in Long COVID risk at 6 months if started in acute phase; BC007 (autoantibody neutraliser) — Phase 2 signal; low-dose naltrexone — observational data positive; antihistamine combination (famotidine + cetirizine) — anecdotal

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large — no proven pharmacotherapy; enormous research investment but no approved treatment as of mid-2026

Primary barrier

biological (mechanism not fully understood) + practice (no evidence-based protocol)

Barrier detail: Long COVID is a heterogeneous syndrome with multiple proposed mechanisms (viral persistence, autoimmunity, microclotting, dysautonomia, mitochondrial dysfunction); no single treatment works for all patients; fragmented care with poor coordination; many clinicians still do not acknowledge Long COVID as a diagnosis

Last SoC change: 2024 — NIH RECOVER initiative released clinical trial protocols for LDN, anticoagulation, anti-viral, and SSRIs; no approved treatment exists; WHO case definition 2021; CDC guidance 2022

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0100096 · EFO: EFO_1002048 · MESH: D000086382 · UMLS_CUI: C5397822

Right to Try Relevance Critical

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Post-Acute COVID/Vaccination Syndrome may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

538

Phase 3: 210, Phase 2: 270, Phase 1: 58

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

104

Actionable

Pipeline Compounds (Top 6)

Darapladib, Fenretinide, Amubarvimab, Aviptadil, Bamlanivimab, Bemnifosbuvir

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

104 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Ageusia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anosmia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABO ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACE2 angiotensin converting enzyme 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGRN agrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGTR1 angiotensin II receptor type 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APOE apolipoprotein E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
B2M beta-2-microglobulin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
B3GLCT beta 3-glucosyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCL11A BCL11 transcription factor A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BECN1 beclin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C3 complement C3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCR1 C-C motif chemokine receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCR3 C-C motif chemokine receptor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CFH complement factor H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CFI complement factor I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHUK component of inhibitor of nuclear factor kappa B kinase complex	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTRB1 chymotrypsinogen B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTRB2 chymotrypsinogen B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A4 cytochrome P450 family 3 subfamily A member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A43 cytochrome P450 family 3 subfamily A member 43	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A5 cytochrome P450 family 3 subfamily A member 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A7 cytochrome P450 family 3 subfamily A member 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DPP9 dipeptidyl peptidase 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ELF5 E74 like ETS transcription factor 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FUBP1 far upstream element binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FURIN furin, paired basic amino acid cleaving enzyme	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FUT2 fucosyltransferase 2 (H blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FUT6 fucosyltransferase 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FYCO1 FYVE and coiled-coil domain autophagy adaptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPC1 glypican 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPC2 glypican 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPC3 glypican 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPC4 glypican 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPC5 glypican 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPC6 glypican 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GUCY1A1 guanylate cyclase 1 soluble subunit alpha 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HAVCR1 hepatitis A virus cellular receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLA-A major histocompatibility complex, class I, A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLA-B major histocompatibility complex, class I, B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLA-C major histocompatibility complex, class I, C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLA-E major histocompatibility complex, class I, E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLA-F major histocompatibility complex, class I, F	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLA-G major histocompatibility complex, class I, G	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLA-H major histocompatibility complex, class I, H (pseudogene)	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
HSPG2 heparan sulfate proteoglycan 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HTRA1 HtrA serine peptidase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNAR2 interferon alpha and beta receptor subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IKBKG inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL10RB interleukin 10 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6 interleukin 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6R interleukin 6 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF3 interferon regulatory factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF5 interferon regulatory factor 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ISG15 ISG15 ubiquitin like modifier	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK1 Janus kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK2 Janus kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LIPC lipase C, hepatic type	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LZTFL1 leucine zipper transcription factor like 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP1LC3B microtubule associated protein 1 light chain 3 beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAVS mitochondrial antiviral signaling protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MUC5B mucin 5B, oligomeric mucus/gel-forming	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C1 nuclear receptor subfamily 3 group C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NRP1 neuropilin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUP210 nucleoporin 210	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
OAS1 2'-5'-oligoadenylate synthetase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
OAS3 2'-5'-oligoadenylate synthetase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Occurrence of COVID-19 Requiring Hospitalization	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3R4 phosphoinositide-3-kinase regulatory subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLSCR1 phospholipid scramblase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTGS2 prostaglandin-endoperoxide synthase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RPN1 ribophorin I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RPS27A ribosomal protein S27a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SDC1 syndecan 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SDC2 syndecan 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SDC3 syndecan 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SDC4 syndecan 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPINC1 serpin family C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SFTPD surfactant protein D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SH2B3 SH2B adaptor protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC22A31 solute carrier family 22 member 31	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC6A20 solute carrier family 6 member 20	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST3GAL3 ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST3GAL4 ST3 beta-galactoside alpha-2,3-sialyltransferase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST6GAL1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST6GALNAC2 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST6GALNAC3 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ST6GALNAC4 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
STING1 stimulator of interferon response cGAMP interactor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAB1 TGF-beta activated kinase 1 (MAP3K7) binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TBK1 TANK binding kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TLR7 toll like receptor 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TLR9 toll like receptor 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TMPRSS2 transmembrane serine protease 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUFM Tu translation elongation factor, mitochondrial	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TYK2 tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
The antibody level against SARS-CoV-2 Receptor Binding Domain measured in blood	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
UVRAG UV radiation resistance associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VDR vitamin D receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ACETAZOLAMIDE	None	Gene-targeted
ADENOVIRUS TYPE 26 ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN	None	Direct
ADUCANUMAB		Gene-targeted
AMIKACIN		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ANAKINRA	None	Direct
ANGIOTENSIN II	agonist	Gene-targeted
ANGIOTENSIN II ACETATE	agonist	Gene-targeted
APIXABAN		Gene-targeted
ASCORBIC ACID		Gene-targeted
ATORVASTATIN		Gene-targeted
ATORVASTATIN CALCIUM TRIHYDRATE		Gene-targeted
AZILSARTAN KAMEDOXOMIL	inhibitor	Gene-targeted
AZILSARTAN MEDOXOMIL	inhibitor; inhibitor	Gene-targeted
BENAZEPRIL		Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BUPROPION HYDROCHLORIDE		Gene-targeted
CANDESARTAN CILEXETIL	inhibitor; inhibitor	Gene-targeted
CAPTOPRIL		Gene-targeted
CARBACHOL	None	Gene-targeted
CHIMPANZEE ADENOVIRUS ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN	None	Direct
CHOLESTEROL		Gene-targeted
CHORIOGONADOTROPIN ALFA		Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
CLOZAPINE		Gene-targeted
CYCLOSPORINE		Gene-targeted
DEXAMETHASONE		Gene-targeted
DIAZEPAM	None	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
DISULFIRAM		Gene-targeted
DONANEMAB		Gene-targeted
DONEPEZIL		Gene-targeted
ELASOMERAN	None	Direct
EPIRUBICIN	None	Gene-targeted
EPROSARTAN	inhibitor	Gene-targeted
EPROSARTAN MESYLATE	inhibitor	Gene-targeted
ETHOXZOLAMIDE	None	Gene-targeted
EXAGAMGLOGENE AUTOTEMCEL		Gene-targeted
FENOFIBRATE MICRONIZED		Gene-targeted
FLUMAZENIL	None	Gene-targeted
FLUVASTATIN		Gene-targeted
GALANTAMINE		Gene-targeted
GANCICLOVIR		Gene-targeted
GENISTEIN		Gene-targeted
HYDROCHLOROTHIAZIDE		Gene-targeted
HYDROGEN PEROXIDE		Gene-targeted
IMIPRAMINE	None	Gene-targeted
INDAPAMIDE	None	Gene-targeted
INDOMETHACIN		Gene-targeted
INDOMETHACIN	None	Gene-targeted
IRBESARTAN	inhibitor; inhibitor	Gene-targeted
IRBESARTAN HYDROCHLORIDE	inhibitor	Gene-targeted
ISOSORBIDE DINITRATE	None	Gene-targeted
LECANEMAB		Gene-targeted
LEVODOPA		Gene-targeted
LISINOPRIL ANHYDROUS		Gene-targeted
LORAZEPAM		Gene-targeted
LOSARTAN POTASSIUM	inhibitor	Gene-targeted
LUTEIN		Gene-targeted
MAFENIDE	None	Gene-targeted
MECAMYLAMINE	None	Gene-targeted
METHAZOLAMIDE	None	Gene-targeted
METHOXSALEN	None	Gene-targeted
METOPROLOL	None	Gene-targeted
MIANSERIN	None	Gene-targeted
NALIDIXIC ACID	None	Gene-targeted
NICOTINE	None	Gene-targeted
NICOTINE POLACRILEX		Gene-targeted
NORETHINDRONE ACETATE		Gene-targeted
NORFLOXACIN	None	Gene-targeted
OFLOXACIN	None	Gene-targeted
OLMESARTAN MEDOXOMIL	inhibitor; inhibitor	Gene-targeted
PEGCETACOPLAN	inhibitor	Gene-targeted
PEMBROLIZUMAB		Gene-targeted
PERINDOPRIL		Gene-targeted
PHENYTOIN	None	Gene-targeted
PRAVASTATIN SODIUM		Gene-targeted
PRAZOSIN	None	Gene-targeted
PREDNISONE		Gene-targeted
REGDANVIMAB	None	Direct
REMDESIVIR	None	Direct
RITONAVIR		Gene-targeted
RIVASTIGMINE		Gene-targeted
SARALASIN ACETATE	inhibitor	Gene-targeted
SARS-COV-2 VIRUS SPIKE PROTEIN	None	Direct
SARS-COV-2 VIRUS, INACTIVATED	None	Direct
SELVACOVATEIN	None	Direct
SIROLIMUS	None	Gene-targeted
SODIUM CHLORIDE		Gene-targeted
SOTROVIMAB	None	Direct
SPARSENTAN	inhibitor; inhibitor	Gene-targeted
SULBACTAM	None	Gene-targeted
TACROLIMUS ANHYDROUS	None	Gene-targeted
TAZOBACTAM	None	Gene-targeted
TELMISARTAN	inhibitor; inhibitor	Gene-targeted
THYROGLOBULIN		Gene-targeted
TOCILIZUMAB	None	Direct
TOZINAMERAN	None	Direct
TRETINOIN		Gene-targeted
TRIAMCINOLONE		Gene-targeted
TROGLITAZONE		Gene-targeted
TROGLITAZONE	None	Gene-targeted
VALSARTAN	inhibitor; inhibitor	Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

From opensourcemed.info/chronic-disease — Metabolic modulation as a therapeutic strategy for post-acute vaccination syndrome (PACVS). Candidates for further study, not approved treatments.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ANAKINRA	Biologic	Approved	Strong	105	7 Cochrane 11 Meta-analysis 16 Trial pubs 12 RCT View evidence Published literature Cochrane review Treatment of multisystem inflammatory syndrome in children (World journal of pediatrics : WJP, 2024) Cochrane review A meta analysis on the utility of Anakinra in severe COVID-19 disease (Cytokine, 2023) Cochrane review Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials (Annals of medicine, 2023) Cochrane review Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis (European journal of medical research, 2023) Cochrane review Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials (Reviews in medical virology, 2023) Meta-analysis Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials (Scientific reports, 2023) Systematic review Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review (BMC infectious diseases, 2024) Systematic review Safety and efficacy of pharmacological approaches available for multisystem inflammatory syndrome in children (MIS-C): a systematic review (The Turkish journal of pediatrics, 2023) Clinical trial publication Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial (Thorax, 2025) Clinical trial publication Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: Association with the inflammatory burden of the host (International journal of antimicrobial agents, 2025) Clinical trial publication Tocilizumab reduces hypercoagulation in COVID-19 - Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial (Thrombosis research, 2024) Clinical trial publication HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL (Shock (Augusta, Ga.), 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BICALUTAMIDE	Small molecule	Approved	Strong	105	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data (European urology, 2022) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
INDOMETHACIN	Small molecule	Approved	Strong	105	21 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NICOTINE	Small molecule	Approved	Strong	105	2 Cochrane 6 Meta-analysis 11 Trial pubs 10 RCT View evidence Published literature Cochrane review Digital interventions for substance use disorders in young people: rapid review (Substance abuse treatment, prevention, and policy, 2023) Cochrane review A review of the characteristic properties of selected tobacco chemicals and their associated etiological risks (Reviews on environmental health, 2023) Meta-analysis Prevalence of cardiovascular risk factors according to Life's Essential 8 in children and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis including 1 526 173 participants from 42 countries (Pediatric obesity, 2025) Meta-analysis Smoking and vaping alter genes related to mechanisms of SARS-CoV-2 susceptibility and severity: a systematic review and meta-analysis (The European respiratory journal, 2024) Meta-analysis Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication (Harm reduction journal, 2021) Meta-analysis A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19 (International journal of environmental research and public health, 2020) Meta-analysis The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7) (Addiction (Abingdon, England), 2021) Systematic review The Intertwining of Posttraumatic Stress Symptoms, Alcohol, Tobacco or Nicotine Use, and the COVID-19 Pandemic: A Systematic Review (International journal of environmental research and public health, 2022) Systematic review Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials (Respiratory medicine and research, 2021) Clinical trial publication Comparison of remote to hybrid methods on recruitment and retention rates in a smoking cessation trial (Drug and alcohol dependence, 2026) Clinical trial publication Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial (JAMA network open, 2023) Clinical trial publication Effect of financial voucher incentives provided with UK stop smoking services on the cessation of smoking in pregnant women (CPIT III): pragmatic, multicentre, single blinded, phase 3, randomised controlled trial (BMJ (Clinical research ed.), 2022) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	105	1 trials View evidence Registry trials NCT05077254 — COVID Protection After Transplant-Immunosuppression Reduction (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TAZOBACTAM	Small molecule	Approved	Strong	105	64 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ADENOVIRUS TYPE 26 ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CHIMPANZEE ADENOVIRUS ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELASOMERAN	Small molecule	Approved	Strong	100	1 trials View evidence Registry trials NCT05077254 — COVID Protection After Transplant-Immunosuppression Reduction (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
REGDANVIMAB	Biologic	Approved	Strong	100	3 Cochrane 1 Meta-analysis 3 Trial pubs 2 RCT View evidence Published literature Cochrane review Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis (British journal of clinical pharmacology, 2023) Cochrane review Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1) (Annals of internal medicine, 2023) Cochrane review SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19 (The Cochrane database of systematic reviews, 2021) Clinical trial publication A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers (EBioMedicine, 2025) Clinical trial publication Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period (Frontiers in immunology, 2023) Clinical trial publication Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection (Clinical therapeutics, 2021) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
REMDESIVIR	Small molecule	Approved	Strong	100	37 Cochrane 42 Meta-analysis 64 Trial pubs 50 RCT View evidence Published literature Cochrane review Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID-19: A Systematic Review and Meta-Analysis (Immunity, inflammation and disease, 2025) Cochrane review Pharmacological and Adjunctive Management of Non-Hospitalized COVID-19 Patients During the Omicron Era: A Systematic Review and Meta-Analysis (Viruses, 2025) Cochrane review Efficacy and safety of 3CL protease inhibitors in patients with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials (Virology journal, 2025) Cochrane review Cardiac adverse events associated with remdesivir in COVID-19 patients: a systematic review and meta-analysis of randomised controlled trials (BMJ open, 2025) Cochrane review Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis (BMJ (Clinical research ed.), 2025) Meta-analysis Remdesivir for the treatment of children hospitalized with COVID-19: a systematic review and meta-analysis (BMC pulmonary medicine, 2026) Systematic review Efficacy and safety of remdesivir for patients with severe acute respiratory syndrome coronavirus 2 infection: A systematic review of randomized controlled trials (Indian journal of pharmacology, 2026) Systematic review Exploring molecular interactions of drugs in different biologically active solvents: A comprehensive review for safe and efficient drug delivery systems (International journal of biological macromolecules, 2026) Clinical trial publication Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease (PloS one, 2026) Clinical trial publication Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes (The Journal of infectious diseases, 2026) Clinical trial publication Pharmacokinetics of SARS-CoV-2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment (Clinical and translational science, 2025) Clinical trial publication Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SARS-COV-2 VIRUS SPIKE PROTEIN	Small molecule	Approved	Strong	100	16 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SARS-COV-2 VIRUS, INACTIVATED	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
SELVACOVATEIN	Biologic	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	100	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Safety and efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia (Respiratory investigation, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SOTROVIMAB	Biologic	Approved	Strong	100	12 Cochrane 13 Meta-analysis 12 Trial pubs 11 RCT View evidence Published literature Cochrane review Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3) (Annals of internal medicine, 2026) Cochrane review Pharmacological and Adjunctive Management of Non-Hospitalized COVID-19 Patients During the Omicron Era: A Systematic Review and Meta-Analysis (Viruses, 2025) Cochrane review Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future (Transplant international : official journal of the European Society for Organ Transplantation, 2025) Cochrane review Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis (Influenza and other respiratory viruses, 2024) Cochrane review Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials (Naunyn-Schmiedeberg's archives of pharmacology, 2024) Meta-analysis Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis (Immunity, inflammation and disease, 2024) Meta-analysis Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis (Expert review of anti-infective therapy, 2024) Clinical trial publication Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical Trial (Drugs in R&D, 2025) Clinical trial publication Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (The Lancet. Infectious diseases, 2026) Clinical trial publication CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease (Scientific reports, 2025) Clinical trial publication Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Clinical trial publication Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves (The Journal of infection, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TOCILIZUMAB	Biologic	Approved	Strong	100	32 Cochrane 49 Meta-analysis 41 Trial pubs 28 RCT View evidence Published literature Cochrane review Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials (The Lancet. Respiratory medicine, 2025) Cochrane review Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis (British journal of clinical pharmacology, 2025) Cochrane review Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis (BMC infectious diseases, 2025) Cochrane review Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review (European journal of clinical pharmacology, 2024) Cochrane review Influence of the COVID-19 Pandemic on Medical Management and on Healthcare Delivery of Immune-Mediated Rheumatic and Musculoskeletal Diseases during the First Pandemic Period February to July 2020: A Systematic Review (Medicina (Kaunas, Lithuania), 2024) Meta-analysis Systemic cytokines drive conserved severity-associated myeloid responses across bacterial and viral infections (Communications biology, 2025) Meta-analysis Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis (Mycoses, 2024) Systematic review Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes (Journal of infection and public health, 2025) Clinical trial publication The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026) Clinical trial publication Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial (Thorax, 2025) Clinical trial publication Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial (BMC infectious diseases, 2025) Clinical trial publication Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial (Infection, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Approved	Strong	100	1 Meta-analysis 2 Trial pubs 2 RCT View evidence Published literature Meta-analysis Vaccines and Bell's palsy: A narrative review (Therapie, 2023) Clinical trial publication Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines (The Journal of infection, 2023) Clinical trial publication Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial (The Lancet. Respiratory medicine, 2022) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADUCANUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIKACIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
APIXABAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCORBIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUPROPION HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CHOLESTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHORIOGONADOTROPIN ALFA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOSPORINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DONANEMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DONEPEZIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPROSARTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPROSARTAN MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EXAGAMGLOGENE AUTOTEMCEL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FENOFIBRATE MICRONIZED Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GALANTAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GANCICLOVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROGEN PEROXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IRBESARTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IRBESARTAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LECANEMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVODOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LISINOPRIL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LORAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOSARTAN POTASSIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LUTEIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE POLACRILEX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORETHINDRONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLMESARTAN MEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PEGCETACOPLAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMBROLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAVASTATIN SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PREDNISONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RITONAVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIVASTIGMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SARALASIN ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SPARSENTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TELMISARTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
THYROGLOBULIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRETINOIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIAMCINOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALSARTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMUBARVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
AVIPTADIL	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BAMLANIVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEMNIFOSBUVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CASIRIVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CILGAVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENSITRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ETESEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
IBUZATRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
IMDEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LUFOTRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
MOLNUPIRAVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIRMATRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
OBELDESIVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROMLUSEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TIXAGEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ABATACEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACALABRUTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALCOHOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMANTADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMOXICILLIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ANDROGRAPHOLIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
APIXABAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
APREMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
APREPITANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARGININE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARTEMETHER	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARTEMISININ	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARTESUNATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AZILSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALOXAVIR MARBOXIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEMIPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BRENSOCATIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROMHEXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROMHEXINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUCILLAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUDESONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BULOXIBUTID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMOSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMOSTAT MESILATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CANDESARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAPTOPRIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CD24FC	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CEFTAROLINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CEFTRIAXONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CENICRIVIROC	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHLOROQUINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHLORPROMAZINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLAVULANIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COLCHICINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COLISTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLO(PROLYLGLYCYL)	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYSTEAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DACLATASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPSONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARUNAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAS-181	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEFEROXAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEUREMIDEVIR HYDROBROMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEUTENZALUTAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIPYRIDAMOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DORNASE ALFA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EDOXABAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENALAPRIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENISAMIUM IODIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENSOVIBEP	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPROSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERITORAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EVOLOCUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FAMOTIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FAVIPIRAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUDROCORTISONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUOXETINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUTICASONE FUROATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUVOXAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOSAPREPITANT DIMEGLUMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOSTAMATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUTAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPARIN CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HONEY	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INOSINE PRANOBEX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTERFERON BETA-1A	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IRBESARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ISOTRETINOIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ITOLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IVERMECTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IXEKIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
JT-001	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETOTIFEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANADELUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEDIPASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEFLUNOMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LENZILUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVAMISOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVILIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVOFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LINAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOPINAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOSMAPIMOD	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LSALT PEPTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LUMEFANTRINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LUMEFANTRINE CO-ARTEMETHER	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LYCOPENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MENAQUINONE 6	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MUPADOLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NADROPARIN CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NAFAMOSTAT MESYLATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NAPROXEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NICORANDIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NITAZOXANIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NITRIC OXIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NOVAFERON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OLMESARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OSELTAMIVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON LAMBDA-1A	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PIPERACILLIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PLITIDEPSIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRASUGREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRUXELUTAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRONARIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REPAGERMANIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REPARIXIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RITONAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RO-0622	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROPEGINTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SABIZABULIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SARILUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SELENIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SILDENAFIL CITRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SILTUXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SODIUM NITRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SOFOSBUVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
STANNOUS FLUORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TENOFOVIR DISOPROXIL FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TICAGRELOR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TINZAPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TINZAPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VALSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B COMPLEX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
XYLITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZAFIRLUKAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZILUCOPLAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZINC ION	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ADERAMASTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ADINTREVIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALSECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANDUSOMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANPOCOGIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEBTELOVIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEMNIFOSBUVIR SULFATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CREXAVIBART	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMVODODSTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENLICOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LARICOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIVALSECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NEZULCITINIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OGALVIBART	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PITOZINAMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PLUTAVIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
POMOTRELVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
QUISOVALIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RAXTOZINAMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RITICOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SORIMCOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TALFIRASTIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TEGRENMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TIBRECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
UPALSECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
VINTESOMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ZANSECIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ZAPNOMETINIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABIVERTINIB MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACEBILUSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE ZIDRIMER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALBUMIN HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALISPORIVIR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALPROSTADIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMBRISENTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMINO ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMIODARONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANISE OIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANNEXIN A5	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTITHROMBIN III HUMAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANUMIGILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APABETALONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARFORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPARTYL-ALANYL-DIKETOPIPERAZINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASUNERCEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATAZANAVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATOVAQUONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVDORALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AXATILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-8797	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZELIRAGON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BARDOXOLONE METHYL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BECLOMETHASONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELNACASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMCENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENZALKONIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERBERINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEXOTEGRAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREQUINAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREQUINAR SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRILACIDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAFICRESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCIFEDIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCIUM DOBESILATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARVACROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEPHARANTHINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CETYLPYRIDINIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHICORIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORHEXIDINE GLUCONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORINE DIOXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLOROQUINE PHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORPHENIRAMINE MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CICLESONIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLARITHROMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLAZAKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLEVUDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLOFAZIMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CO-TRIMOXAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CRIZANLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
D6-25-HYDROXYVITAMIN D3	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALCETRAPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DANICOPAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAPANSUTRILE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAZCAPISTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DECITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DERAMIOCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DESIDUSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DESOXYRIBONUCLEASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIACEREIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DISULFIRAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOCIPARSTAT SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DONIDALORSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUTASTERIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUVELISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EBSELEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECULIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFINEPTAKIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFLEPEDOCOKIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELEUTHERO	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMETINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMIPLACEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENIBARCIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENSIFENTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENZALUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPOPROSTENOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTETROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRADIOL CYPIONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EZURPIMTROSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FINGOLIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FISETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORALUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GENISTEIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-2586881	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HESPERIDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYALURONATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROGEN PEROXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUDILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IC14	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICATIBANT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFENPRODIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ILOPROST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON BETA-1B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOQUERCETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISUZINAXIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
K-777	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LACTOFERRIN, BOVINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIOTHYRONINE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LORATADINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MANNITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MARAVIROC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAS-825	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAVRILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MERIMEPODIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METENKEFALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLENE BLUE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MONALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NANGIBOTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NARSOPLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NICLOSAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NICOTINAMIDE RIBOSIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYTOCIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OZANIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PACRITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALMIDROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMAPIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMREVLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PARIDIPRUBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PICLIDENOSON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIRFENIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLONMARLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POVIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POVIDONE-IODINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROBENECID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYRUVATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUININE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMATROBAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMELTEON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAZUPROTAFIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RBT-9	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIVAROXABAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAB-185	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELINEXOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SENICAPOC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILMITASERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIMNOTRELVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIRUKUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM THIOSULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULODEXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAFENOQUINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELACEBEC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMPOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENECTEPLASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENOFOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THYMALFASIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THYMOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREMIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRABEDERSEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRANEXAMIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRETINOIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIDECACTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRV-120027	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UPANOVIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALACYCLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VANILLIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARESPLADIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VB-201	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VERAPAMIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VIDOFLUDIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
WAX, EMULSIFYING	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZANUBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZAVEGEPANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZIMLOVISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZUNSEMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABZ-SER-PRO-TYR(NO2)-OH Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
AL-78898A Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALUNACEDASE ALFA Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
AMY-101 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ANTI-PD-L1 MONOCLONAL ANTIBODY Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
BCY15291 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPOUND 28 [PMID: 18324760] Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPSTATIN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
CPS4 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
DX600 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
MLN-4760 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ORE-1001 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
POT-4 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TASOSARTAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
XNT [PMID: 18391097] Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BELUDAVIMAB	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ECLITASERTIB	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENPATORAN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENSITRELVIR FUMARATE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
GORIVITUG	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LARSUCOSTEROL	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LARSUCOSTEROL SODIUM	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ONTERNABEZ	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEMIVIBART	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRANSCROCETIN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
(+)-MENTHOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ABC-294640	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALPHA-TOCOPHEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEMPEGALDESLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BROMELAINS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CALCIUM CARBONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DICLOFENAC SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIOSMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DVX-201	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALIDESIVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IODINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGNESIUM CITRATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MANGANESE SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MENTHOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHYL SALICYLATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
N-HYDROXYCYTIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NALTREXONE HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NITROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NOGAPENDEKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NVX-COV2373	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OLITIGALTIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2B	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PHENFORMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
POTASSIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PROTOPORPHYRIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REGADENOSON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINTATOLIMOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SACUBITRIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SARS-COV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SILDENAFIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TANIRALEUCEL	Cell therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TOPOTECAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRAMADOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ULINASTATIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UPROLESELAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
WP-1122	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XANTHOHUMOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZELPULTIDE ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZOTATIFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
Acetyl-L-carnitine OSMF review	Supplement	Preclinical	Emerging	30	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Clinical usefulness of nutraceutics with acetyl-L-carnitine, α-lipoic acid, phosphatidylserine, curcumin, C, E and B-group vitamins in patients awaiting for carpal tunnel release during COVID-19 pandemic: a randomized controlled open label prospective study (Acta bio-medica : Atenei Parmensis, 2023) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Coenzyme Q10 OSMF review	Supplement	Preclinical	Emerging	30	—	OSMF Chronic Disease Review	OSMF Review Citation
Creatine OSMF review	Supplement	Preclinical	Emerging	30	15 Cochrane 28 Meta-analysis 14 Trial pubs 12 RCT View evidence Published literature Cochrane review Prevalence of Cardiovascular Complications in Coronavirus Disease 2019 adult Patients: A Systematic Review and Meta-Analysis (Iranian journal of medical sciences, 2023) Cochrane review Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis (Immunity, inflammation and disease, 2021) Cochrane review Serum biomarkers for prediction of mortality in patients with COVID-19 (Annals of clinical biochemistry, 2022) Cochrane review The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis (Archives of virology, 2021) Cochrane review Update on SARS-CoV-2 infection in children (Paediatrics and international child health, 2021) Meta-analysis A composite ranking of risk factors for COVID-19 time-to-event data from a Turkish cohort (Computational biology and chemistry, 2022) Meta-analysis Cardiac biomarkers and COVID-19: A systematic review and meta-analysis (Journal of infection and public health, 2021) Meta-analysis Cystatin C, COVID-19 severity and mortality: a systematic review and meta-analysis (Journal of nephrology, 2022) Systematic review Hashimoto's thyroiditis-related myopathy in a patient with SARS-CoV-2 infection: A case report and systematic literature review (Medicine, 2023) Clinical trial publication Metabolic reprogramming of endothelial-related pathways in COVID-19 patients treated with hyperbaric oxygen therapy: a randomized clinical trial (Scientific reports, 2026) Clinical trial publication The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial (European journal of nutrition, 2024) Clinical trial publication The effects of inspiratory muscle training on biomarkers of muscle damage in recovered COVID-19 patients after weaning from mechanical ventilation (Chronic respiratory disease, 2024) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
GLP-1 receptor agonists OSMF review	Biologic	Preclinical	Emerging	30	—	OSMF Chronic Disease Review	OSMF Review Citation
L-Citrulline OSMF review	Supplement	Preclinical	Emerging	30	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effect of L-Citrulline Supplementation on Endothelial Function and Body Composition in Post-COVID-19 Syndrome: A Randomized Clinical Trial (Nutrients, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Low-dose naltrexone (LDN) OSMF review	Small molecule	Preclinical	Emerging	30	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Methylene blue OSMF review	Small molecule	Preclinical	Emerging	30	—	OSMF Chronic Disease Review	OSMF Review Citation
N-acetylcysteine (NAC) OSMF review	Supplement	Preclinical	Emerging	30	1 Cochrane 4 Meta-analysis 3 Trial pubs 3 RCT View evidence Published literature Cochrane review Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials (Inflammopharmacology, 2025) Meta-analysis COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2 (Cellular and molecular biology (Noisy-le-Grand, France), 2025) Meta-analysis Is N -acetylcysteine effective in treating patients with coronavirus disease 2019? A meta-analysis (Journal of the Chinese Medical Association : JCMA, 2023) Meta-analysis N-acetylcysteine efficacy in patients hospitalized with COVID-19 pneumonia: a systematic review and meta-analysis (Romanian journal of internal medicine = Revue roumaine de medecine interne, 2023) Clinical trial publication Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 (Nutrients, 2023) Clinical trial publication Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial (Journal of medical virology, 2023) Clinical trial publication A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome (Pharmacological reports : PR, 2021) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
NMN (NAD+ precursors) OSMF review	Supplement	Preclinical	Emerging	30	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Taurine OSMF review	Supplement	Preclinical	Emerging	30	2 Cochrane 2 Meta-analysis 1 Trial pubs View evidence Published literature Cochrane review Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis (BMC infectious diseases, 2026) Cochrane review Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis (Journal of global health, 2025) Clinical trial publication The serum amino acid profile in COVID-19 (Amino acids, 2021) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Vitamin C (High-dose) OSMF review	Supplement	Preclinical	Emerging	30	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
ALBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANGIOTENSIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
APROTININ	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BERACTANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIVALIRUDIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLUENZA A VIRUS, SPLIT VIRION	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLUENZA VIRUS VACCINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN 6	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NETAKIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NITROGLYCERIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLOKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PHOLCODINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PORACTANT ALFA	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUININE SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SILVER	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIVELESTAT SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SODIUM BICARBONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TERFENADINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE HEXACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
URSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ANAKINRA	Biologic	Approved	Strong	105	7 Cochrane 11 Meta-analysis 16 Trial pubs 12 RCT View evidence Published literature Cochrane review Treatment of multisystem inflammatory syndrome in children (World journal of pediatrics : WJP, 2024) Cochrane review A meta analysis on the utility of Anakinra in severe COVID-19 disease (Cytokine, 2023) Cochrane review Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials (Annals of medicine, 2023) Cochrane review Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis (European journal of medical research, 2023) Cochrane review Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials (Reviews in medical virology, 2023) Meta-analysis Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials (Scientific reports, 2023) Systematic review Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review (BMC infectious diseases, 2024) Systematic review Safety and efficacy of pharmacological approaches available for multisystem inflammatory syndrome in children (MIS-C): a systematic review (The Turkish journal of pediatrics, 2023) Clinical trial publication Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial (Thorax, 2025) Clinical trial publication Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: Association with the inflammatory burden of the host (International journal of antimicrobial agents, 2025) Clinical trial publication Tocilizumab reduces hypercoagulation in COVID-19 - Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial (Thrombosis research, 2024) Clinical trial publication HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL (Shock (Augusta, Ga.), 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ADENOVIRUS TYPE 26 ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CHIMPANZEE ADENOVIRUS ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ELASOMERAN	Small molecule	Approved	Strong	100	1 trials View evidence Registry trials NCT05077254 — COVID Protection After Transplant-Immunosuppression Reduction (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
REGDANVIMAB	Biologic	Approved	Strong	100	3 Cochrane 1 Meta-analysis 3 Trial pubs 2 RCT View evidence Published literature Cochrane review Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis (British journal of clinical pharmacology, 2023) Cochrane review Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1) (Annals of internal medicine, 2023) Cochrane review SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19 (The Cochrane database of systematic reviews, 2021) Clinical trial publication A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers (EBioMedicine, 2025) Clinical trial publication Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period (Frontiers in immunology, 2023) Clinical trial publication Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection (Clinical therapeutics, 2021) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
REMDESIVIR	Small molecule	Approved	Strong	100	37 Cochrane 42 Meta-analysis 64 Trial pubs 50 RCT View evidence Published literature Cochrane review Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID-19: A Systematic Review and Meta-Analysis (Immunity, inflammation and disease, 2025) Cochrane review Pharmacological and Adjunctive Management of Non-Hospitalized COVID-19 Patients During the Omicron Era: A Systematic Review and Meta-Analysis (Viruses, 2025) Cochrane review Efficacy and safety of 3CL protease inhibitors in patients with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials (Virology journal, 2025) Cochrane review Cardiac adverse events associated with remdesivir in COVID-19 patients: a systematic review and meta-analysis of randomised controlled trials (BMJ open, 2025) Cochrane review Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis (BMJ (Clinical research ed.), 2025) Meta-analysis Remdesivir for the treatment of children hospitalized with COVID-19: a systematic review and meta-analysis (BMC pulmonary medicine, 2026) Systematic review Efficacy and safety of remdesivir for patients with severe acute respiratory syndrome coronavirus 2 infection: A systematic review of randomized controlled trials (Indian journal of pharmacology, 2026) Systematic review Exploring molecular interactions of drugs in different biologically active solvents: A comprehensive review for safe and efficient drug delivery systems (International journal of biological macromolecules, 2026) Clinical trial publication Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease (PloS one, 2026) Clinical trial publication Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes (The Journal of infectious diseases, 2026) Clinical trial publication Pharmacokinetics of SARS-CoV-2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment (Clinical and translational science, 2025) Clinical trial publication Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SARS-COV-2 VIRUS SPIKE PROTEIN	Small molecule	Approved	Strong	100	16 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SARS-COV-2 VIRUS, INACTIVATED	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
SELVACOVATEIN	Biologic	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SOTROVIMAB	Biologic	Approved	Strong	100	12 Cochrane 13 Meta-analysis 12 Trial pubs 11 RCT View evidence Published literature Cochrane review Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3) (Annals of internal medicine, 2026) Cochrane review Pharmacological and Adjunctive Management of Non-Hospitalized COVID-19 Patients During the Omicron Era: A Systematic Review and Meta-Analysis (Viruses, 2025) Cochrane review Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future (Transplant international : official journal of the European Society for Organ Transplantation, 2025) Cochrane review Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis (Influenza and other respiratory viruses, 2024) Cochrane review Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials (Naunyn-Schmiedeberg's archives of pharmacology, 2024) Meta-analysis Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis (Immunity, inflammation and disease, 2024) Meta-analysis Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis (Expert review of anti-infective therapy, 2024) Clinical trial publication Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical Trial (Drugs in R&D, 2025) Clinical trial publication Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (The Lancet. Infectious diseases, 2026) Clinical trial publication CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease (Scientific reports, 2025) Clinical trial publication Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025) Clinical trial publication Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves (The Journal of infection, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TOCILIZUMAB	Biologic	Approved	Strong	100	32 Cochrane 49 Meta-analysis 41 Trial pubs 28 RCT View evidence Published literature Cochrane review Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials (The Lancet. Respiratory medicine, 2025) Cochrane review Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis (British journal of clinical pharmacology, 2025) Cochrane review Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis (BMC infectious diseases, 2025) Cochrane review Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review (European journal of clinical pharmacology, 2024) Cochrane review Influence of the COVID-19 Pandemic on Medical Management and on Healthcare Delivery of Immune-Mediated Rheumatic and Musculoskeletal Diseases during the First Pandemic Period February to July 2020: A Systematic Review (Medicina (Kaunas, Lithuania), 2024) Meta-analysis Systemic cytokines drive conserved severity-associated myeloid responses across bacterial and viral infections (Communications biology, 2025) Meta-analysis Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis (Mycoses, 2024) Systematic review Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes (Journal of infection and public health, 2025) Clinical trial publication The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026) Clinical trial publication Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial (Thorax, 2025) Clinical trial publication Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial (BMC infectious diseases, 2025) Clinical trial publication Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial (Infection, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Approved	Strong	100	1 Meta-analysis 2 Trial pubs 2 RCT View evidence Published literature Meta-analysis Vaccines and Bell's palsy: A narrative review (Therapie, 2023) Clinical trial publication Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines (The Journal of infection, 2023) Clinical trial publication Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial (The Lancet. Respiratory medicine, 2022) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AMUBARVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
AVIPTADIL	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BAMLANIVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEMNIFOSBUVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CASIRIVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CILGAVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENSITRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ETESEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
IBUZATRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
IMDEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LUFOTRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
MOLNUPIRAVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIRMATRELVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
OBELDESIVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROMLUSEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TIXAGEVIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ABATACEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACALABRUTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALCOHOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMANTADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMOXICILLIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ANDROGRAPHOLIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
APIXABAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
APREMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
APREPITANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARGININE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARTEMETHER	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARTEMISININ	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARTESUNATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AZILSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALOXAVIR MARBOXIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEMIPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BICALUTAMIDE	Small molecule	Phase III	Moderate	80	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data (European urology, 2022) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
BRENSOCATIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROMHEXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROMHEXINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUCILLAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUDESONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BULOXIBUTID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMOSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMOSTAT MESILATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CANDESARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAPTOPRIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CD24FC	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CEFTAROLINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CEFTRIAXONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CENICRIVIROC	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHLOROQUINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHLORPROMAZINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLAVULANIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COLCHICINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COLISTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLO(PROLYLGLYCYL)	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYSTEAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DACLATASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAPSONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARUNAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAS-181	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEFEROXAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEUREMIDEVIR HYDROBROMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEUTENZALUTAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIPYRIDAMOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DORNASE ALFA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EDOXABAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENALAPRIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENISAMIUM IODIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENSOVIBEP	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPROSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERITORAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EVOLOCUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FAMOTIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FAVIPIRAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUDROCORTISONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUOXETINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUTICASONE FUROATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUVOXAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOSAPREPITANT DIMEGLUMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOSTAMATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLUTAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPARIN CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HONEY	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INDOMETHACIN	Small molecule	Phase III	Moderate	80	21 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INOSINE PRANOBEX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTERFERON BETA-1A	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IRBESARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ISOTRETINOIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ITOLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IVERMECTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IXEKIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
JT-001	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETOTIFEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANADELUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEDIPASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEFLUNOMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LENZILUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVAMISOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVILIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVOFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LINAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOPINAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOSMAPIMOD	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LSALT PEPTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LUMEFANTRINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LUMEFANTRINE CO-ARTEMETHER	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LYCOPENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MENAQUINONE 6	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MUPADOLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NADROPARIN CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NAFAMOSTAT MESYLATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NAPROXEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NICORANDIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NICOTINE	Small molecule	Phase III	Moderate	80	2 Cochrane 6 Meta-analysis 11 Trial pubs 10 RCT View evidence Published literature Cochrane review Digital interventions for substance use disorders in young people: rapid review (Substance abuse treatment, prevention, and policy, 2023) Cochrane review A review of the characteristic properties of selected tobacco chemicals and their associated etiological risks (Reviews on environmental health, 2023) Meta-analysis Prevalence of cardiovascular risk factors according to Life's Essential 8 in children and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis including 1 526 173 participants from 42 countries (Pediatric obesity, 2025) Meta-analysis Smoking and vaping alter genes related to mechanisms of SARS-CoV-2 susceptibility and severity: a systematic review and meta-analysis (The European respiratory journal, 2024) Meta-analysis Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication (Harm reduction journal, 2021) Meta-analysis A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19 (International journal of environmental research and public health, 2020) Meta-analysis The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7) (Addiction (Abingdon, England), 2021) Systematic review The Intertwining of Posttraumatic Stress Symptoms, Alcohol, Tobacco or Nicotine Use, and the COVID-19 Pandemic: A Systematic Review (International journal of environmental research and public health, 2022) Systematic review Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials (Respiratory medicine and research, 2021) Clinical trial publication Comparison of remote to hybrid methods on recruitment and retention rates in a smoking cessation trial (Drug and alcohol dependence, 2026) Clinical trial publication Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial (JAMA network open, 2023) Clinical trial publication Effect of financial voucher incentives provided with UK stop smoking services on the cessation of smoking in pregnant women (CPIT III): pragmatic, multicentre, single blinded, phase 3, randomised controlled trial (BMJ (Clinical research ed.), 2022) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
NITAZOXANIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NITRIC OXIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NOVAFERON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OLMESARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OSELTAMIVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON LAMBDA-1A	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PIPERACILLIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PLITIDEPSIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRASUGREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRUXELUTAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYRONARIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REPAGERMANIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REPARIXIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RITONAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RO-0622	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROPEGINTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SABIZABULIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SARILUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SELENIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SILDENAFIL CITRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SILTUXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SODIUM NITRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SOFOSBUVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
STANNOUS FLUORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Phase III	Moderate	80	1 trials View evidence Registry trials NCT05077254 — COVID Protection After Transplant-Immunosuppression Reduction (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
TAZOBACTAM	Small molecule	Phase III	Moderate	80	64 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TENOFOVIR DISOPROXIL FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TICAGRELOR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TINZAPARIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TINZAPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VALSARTAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VITAMIN B COMPLEX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
XYLITOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZAFIRLUKAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZILUCOPLAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZINC ION	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ADERAMASTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ADINTREVIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALSECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANDUSOMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANPOCOGIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEBTELOVIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEMNIFOSBUVIR SULFATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CREXAVIBART	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMVODODSTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENLICOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LARICOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIVALSECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NEZULCITINIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OGALVIBART	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PITOZINAMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PLUTAVIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
POMOTRELVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
QUISOVALIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RAXTOZINAMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RITICOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SORIMCOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TALFIRASTIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TEGRENMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TIBRECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
UPALSECOVATEIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
VINTESOMERAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ZANSECIMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ZAPNOMETINIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABIVERTINIB MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACEBILUSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE ZIDRIMER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALBUMIN HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALISPORIVIR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALPROSTADIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMBRISENTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMINO ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMIODARONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANISE OIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANNEXIN A5	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTITHROMBIN III HUMAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANUMIGILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APABETALONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARFORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPARTYL-ALANYL-DIKETOPIPERAZINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASUNERCEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATAZANAVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATOVAQUONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVDORALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AXATILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-8797	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZELIRAGON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BARDOXOLONE METHYL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BECLOMETHASONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELNACASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMCENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENZALKONIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERBERINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEXOTEGRAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREQUINAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREQUINAR SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRILACIDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAFICRESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCIFEDIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCIUM DOBESILATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARVACROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEPHARANTHINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CETYLPYRIDINIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHICORIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORHEXIDINE GLUCONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORINE DIOXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLOROQUINE PHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLORPHENIRAMINE MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CICLESONIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIPROFLOXACIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLARITHROMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLAZAKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLEVUDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLOFAZIMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CO-TRIMOXAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CRIZANLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
D6-25-HYDROXYVITAMIN D3	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALCETRAPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DANICOPAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAPANSUTRILE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAZCAPISTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DECITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DERAMIOCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DESIDUSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DESOXYRIBONUCLEASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIACEREIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DISULFIRAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOCIPARSTAT SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DONIDALORSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUTASTERIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUVELISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EBSELEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECULIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFINEPTAKIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFLEPEDOCOKIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELEUTHERO	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMETINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMIPLACEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENIBARCIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENSIFENTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENZALUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPOPROSTENOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTETROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRADIOL CYPIONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EZURPIMTROSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FINGOLIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FISETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORALUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GENISTEIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-2586881	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HESPERIDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYALURONATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROGEN PEROXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUDILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IC14	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICATIBANT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFENPRODIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ILOPROST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON BETA-1B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOQUERCETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISUZINAXIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
K-777	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LACTOFERRIN, BOVINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIOTHYRONINE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LORATADINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MANNITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MARAVIROC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAS-825	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAVRILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MERIMEPODIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METENKEFALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLENE BLUE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MONALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NANGIBOTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NARSOPLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NICLOSAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NICOTINAMIDE RIBOSIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYTOCIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OZANIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PACRITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALMIDROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMAPIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMREVLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PARIDIPRUBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PICLIDENOSON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIRFENIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLONMARLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POVIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POVIDONE-IODINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROBENECID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYRUVATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUININE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMATROBAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMELTEON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAZUPROTAFIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RBT-9	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIVAROXABAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAB-185	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELINEXOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SENICAPOC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILMITASERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIMNOTRELVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIROLIMUS	Small molecule	Phase II	Emerging	60	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Safety and efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia (Respiratory investigation, 2024) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
SIRUKUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM THIOSULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULODEXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAFENOQUINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELACEBEC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMPOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENECTEPLASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENOFOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THYMALFASIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THYMOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREMIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRABEDERSEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRANEXAMIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRETINOIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIDECACTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRV-120027	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UPANOVIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALACYCLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VANILLIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARESPLADIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VB-201	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VERAPAMIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VIDOFLUDIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
WAX, EMULSIFYING	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZANUBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZAVEGEPANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZIMLOVISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZUNSEMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELUDAVIMAB	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ECLITASERTIB	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENPATORAN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENSITRELVIR FUMARATE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
GORIVITUG	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LARSUCOSTEROL	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LARSUCOSTEROL SODIUM	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ONTERNABEZ	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEMIVIBART	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRANSCROCETIN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
(+)-MENTHOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ABC-294640	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALPHA-TOCOPHEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEMPEGALDESLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BROMELAINS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CALCIUM CARBONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DICLOFENAC SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIOSMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DVX-201	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALIDESIVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IODINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGNESIUM CITRATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MANGANESE SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MENTHOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHYL SALICYLATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
N-HYDROXYCYTIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NALTREXONE HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NITROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NOGAPENDEKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NVX-COV2373	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OLITIGALTIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2B	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PHENFORMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
POTASSIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PROTOPORPHYRIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REGADENOSON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINTATOLIMOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SACUBITRIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SARS-COV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SILDENAFIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TANIRALEUCEL	Cell therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TOPOTECAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRAMADOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ULINASTATIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UPROLESELAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
WP-1122	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XANTHOHUMOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZELPULTIDE ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZOTATIFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANGIOTENSIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
APROTININ	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BERACTANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIVALIRUDIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLUENZA A VIRUS, SPLIT VIRION	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLUENZA VIRUS VACCINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN 6	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NETAKIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NITROGLYCERIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLOKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PHOLCODINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PORACTANT ALFA	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUININE SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SILVER	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIVELESTAT SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SODIUM BICARBONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TERFENADINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE HEXACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
URSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADUCANUMAB Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIKACIN Repurposing via B2M	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
APIXABAN Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCORBIC ACID Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data (European urology, 2022) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
BUPROPION HYDROCHLORIDE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CHOLESTEROL Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
CHORIOGONADOTROPIN ALFA Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOZAPINE Repurposing via C3	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOSPORINE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DISULFIRAM Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
DONANEMAB Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
DONEPEZIL Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPROSARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
EPROSARTAN MESYLATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EXAGAMGLOGENE AUTOTEMCEL Repurposing via BCL11A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FENOFIBRATE MICRONIZED Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUVASTATIN Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
GALANTAMINE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
GANCICLOVIR Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
GENISTEIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROGEN PEROXIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
INDOMETHACIN Repurposing via ABO	Small molecule	Approved	Strong	95	21 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
IRBESARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
IRBESARTAN HYDROCHLORIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LECANEMAB Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVODOPA Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
LISINOPRIL ANHYDROUS Repurposing via ACE2	Small molecule	Approved	Strong	95	—	DGIdb	—
LORAZEPAM Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
LOSARTAN POTASSIUM Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
LUTEIN Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing via ABO	Small molecule	Approved	Strong	95	2 Cochrane 6 Meta-analysis 11 Trial pubs 10 RCT View evidence Published literature Cochrane review Digital interventions for substance use disorders in young people: rapid review (Substance abuse treatment, prevention, and policy, 2023) Cochrane review A review of the characteristic properties of selected tobacco chemicals and their associated etiological risks (Reviews on environmental health, 2023) Meta-analysis Prevalence of cardiovascular risk factors according to Life's Essential 8 in children and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis including 1 526 173 participants from 42 countries (Pediatric obesity, 2025) Meta-analysis Smoking and vaping alter genes related to mechanisms of SARS-CoV-2 susceptibility and severity: a systematic review and meta-analysis (The European respiratory journal, 2024) Meta-analysis Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication (Harm reduction journal, 2021) Meta-analysis A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19 (International journal of environmental research and public health, 2020) Meta-analysis The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7) (Addiction (Abingdon, England), 2021) Systematic review The Intertwining of Posttraumatic Stress Symptoms, Alcohol, Tobacco or Nicotine Use, and the COVID-19 Pandemic: A Systematic Review (International journal of environmental research and public health, 2022) Systematic review Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials (Respiratory medicine and research, 2021) Clinical trial publication Comparison of remote to hybrid methods on recruitment and retention rates in a smoking cessation trial (Drug and alcohol dependence, 2026) Clinical trial publication Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial (JAMA network open, 2023) Clinical trial publication Effect of financial voucher incentives provided with UK stop smoking services on the cessation of smoking in pregnant women (CPIT III): pragmatic, multicentre, single blinded, phase 3, randomised controlled trial (BMJ (Clinical research ed.), 2022) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NICOTINE POLACRILEX Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
NORETHINDRONE ACETATE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
NORFLOXACIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLMESARTAN MEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
PEGCETACOPLAN Repurposing via C3	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMBROLIZUMAB Repurposing via B2M	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAVASTATIN SODIUM Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PREDNISONE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
RITONAVIR Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
RIVASTIGMINE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
SARALASIN ACETATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SIROLIMUS Repurposing via ABO	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Safety and efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia (Respiratory investigation, 2024) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
SPARSENTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ABO	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT05077254 — COVID Protection After Transplant-Immunosuppression Reduction (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing via ABO	Small molecule	Approved	Strong	95	64 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TELMISARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
THYROGLOBULIN Repurposing via B2M	Small molecule	Approved	Strong	95	—	DGIdb	—
TRETINOIN Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIAMCINOLONE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALSARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via ABO	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ABO	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ABZ-SER-PRO-TYR(NO2)-OH Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
AL-78898A Repurposing via C3	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALUNACEDASE ALFA Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
AMY-101 Repurposing via C3	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ANTI-PD-L1 MONOCLONAL ANTIBODY Repurposing via B2M	Small molecule	Phase II	Emerging	50	—	DGIdb	—
BCY15291 Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPOUND 28 [PMID: 18324760] Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPSTATIN Repurposing via C3	Small molecule	Phase II	Emerging	50	—	DGIdb	—
CPS4 Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
DX600 Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
MLN-4760 Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ORE-1001 Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
POT-4 Repurposing via C3	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TASOSARTAN Repurposing via AGTR1	Small molecule	Phase II	Emerging	50	—	DGIdb	—
XNT [PMID: 18391097] Repurposing via ACE2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ABO	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Acetyl-L-carnitine OSMF review	Supplement	Preclinical	Emerging	30	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Clinical usefulness of nutraceutics with acetyl-L-carnitine, α-lipoic acid, phosphatidylserine, curcumin, C, E and B-group vitamins in patients awaiting for carpal tunnel release during COVID-19 pandemic: a randomized controlled open label prospective study (Acta bio-medica : Atenei Parmensis, 2023) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Coenzyme Q10 OSMF review	Supplement	Preclinical	Emerging	30	—	OSMF Chronic Disease Review	OSMF Review Citation
Creatine OSMF review	Supplement	Preclinical	Emerging	30	15 Cochrane 28 Meta-analysis 14 Trial pubs 12 RCT View evidence Published literature Cochrane review Prevalence of Cardiovascular Complications in Coronavirus Disease 2019 adult Patients: A Systematic Review and Meta-Analysis (Iranian journal of medical sciences, 2023) Cochrane review Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis (Immunity, inflammation and disease, 2021) Cochrane review Serum biomarkers for prediction of mortality in patients with COVID-19 (Annals of clinical biochemistry, 2022) Cochrane review The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis (Archives of virology, 2021) Cochrane review Update on SARS-CoV-2 infection in children (Paediatrics and international child health, 2021) Meta-analysis A composite ranking of risk factors for COVID-19 time-to-event data from a Turkish cohort (Computational biology and chemistry, 2022) Meta-analysis Cardiac biomarkers and COVID-19: A systematic review and meta-analysis (Journal of infection and public health, 2021) Meta-analysis Cystatin C, COVID-19 severity and mortality: a systematic review and meta-analysis (Journal of nephrology, 2022) Systematic review Hashimoto's thyroiditis-related myopathy in a patient with SARS-CoV-2 infection: A case report and systematic literature review (Medicine, 2023) Clinical trial publication Metabolic reprogramming of endothelial-related pathways in COVID-19 patients treated with hyperbaric oxygen therapy: a randomized clinical trial (Scientific reports, 2026) Clinical trial publication The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial (European journal of nutrition, 2024) Clinical trial publication The effects of inspiratory muscle training on biomarkers of muscle damage in recovered COVID-19 patients after weaning from mechanical ventilation (Chronic respiratory disease, 2024) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
GLP-1 receptor agonists OSMF review	Biologic	Preclinical	Emerging	30	—	OSMF Chronic Disease Review	OSMF Review Citation
L-Citrulline OSMF review	Supplement	Preclinical	Emerging	30	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effect of L-Citrulline Supplementation on Endothelial Function and Body Composition in Post-COVID-19 Syndrome: A Randomized Clinical Trial (Nutrients, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Low-dose naltrexone (LDN) OSMF review	Small molecule	Preclinical	Emerging	30	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Methylene blue OSMF review	Small molecule	Preclinical	Emerging	30	—	OSMF Chronic Disease Review	OSMF Review Citation
N-acetylcysteine (NAC) OSMF review	Supplement	Preclinical	Emerging	30	1 Cochrane 4 Meta-analysis 3 Trial pubs 3 RCT View evidence Published literature Cochrane review Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials (Inflammopharmacology, 2025) Meta-analysis COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2 (Cellular and molecular biology (Noisy-le-Grand, France), 2025) Meta-analysis Is N -acetylcysteine effective in treating patients with coronavirus disease 2019? A meta-analysis (Journal of the Chinese Medical Association : JCMA, 2023) Meta-analysis N-acetylcysteine efficacy in patients hospitalized with COVID-19 pneumonia: a systematic review and meta-analysis (Romanian journal of internal medicine = Revue roumaine de medecine interne, 2023) Clinical trial publication Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 (Nutrients, 2023) Clinical trial publication Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial (Journal of medical virology, 2023) Clinical trial publication A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome (Pharmacological reports : PR, 2021) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
NMN (NAD+ precursors) OSMF review	Supplement	Preclinical	Emerging	30	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Taurine OSMF review	Supplement	Preclinical	Emerging	30	2 Cochrane 2 Meta-analysis 1 Trial pubs View evidence Published literature Cochrane review Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis (BMC infectious diseases, 2026) Cochrane review Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis (Journal of global health, 2025) Clinical trial publication The serum amino acid profile in COVID-19 (Amino acids, 2021) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Vitamin C (High-dose) OSMF review	Supplement	Preclinical	Emerging	30	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation

Natural Products

10 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Trials & literature	Sources	Links
Ore-1001 Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Hematein Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Myricetin Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Chloroquine Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Hydroxychloroquine Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Eprosartan Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Irbesartan Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Valsartan Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Tasosartan Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Losartan Potassium Natural product	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.